Russell Investments Group Ltd. Boosts Stake in Inari Medical, Inc. (NASDAQ:NARI)

Russell Investments Group Ltd. boosted its position in shares of Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 139.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,485 shares of the company's stock after acquiring an additional 28,825 shares during the quarter. Russell Investments Group Ltd. owned 0.09% of Inari Medical worth $3,213,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in NARI. Fifth Third Bancorp increased its stake in shares of Inari Medical by 54.3% during the 3rd quarter. Fifth Third Bancorp now owns 486 shares of the company's stock worth $32,000 after purchasing an additional 171 shares during the last quarter. New York State Teachers Retirement System increased its position in Inari Medical by 0.4% during the fourth quarter. New York State Teachers Retirement System now owns 53,924 shares of the company's stock worth $3,501,000 after buying an additional 233 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Inari Medical by 11.7% in the third quarter. Teacher Retirement System of Texas now owns 3,987 shares of the company's stock valued at $261,000 after buying an additional 417 shares during the period. State Board of Administration of Florida Retirement System lifted its position in shares of Inari Medical by 3.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 15,276 shares of the company's stock valued at $999,000 after buying an additional 560 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Inari Medical by 7.8% during the 3rd quarter. Victory Capital Management Inc. now owns 9,050 shares of the company's stock worth $592,000 after acquiring an additional 651 shares during the period. Institutional investors and hedge funds own 90.98% of the company's stock.

Inari Medical Stock Up 4.2 %

Shares of NASDAQ:NARI traded up $1.83 during trading on Monday, reaching $45.58. 1,312,115 shares of the company traded hands, compared to its average volume of 1,168,496. The firm has a market capitalization of $2.65 billion, a PE ratio of -111.56 and a beta of 0.93. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $71.85. The company's 50 day moving average is $42.08 and its two-hundred day moving average is $53.13.

Inari Medical (NASDAQ:NARI - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. The firm had revenue of $132.10 million for the quarter, compared to the consensus estimate of $131.82 million. During the same period in the prior year, the company earned ($0.11) EPS. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, research analysts anticipate that Inari Medical, Inc. will post -0.41 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on NARI shares. Wells Fargo & Company cut their price target on Inari Medical from $100.00 to $84.00 and set an "overweight" rating for the company in a report on Wednesday, May 1st. Canaccord Genuity Group decreased their price target on shares of Inari Medical from $75.00 to $55.00 and set a "buy" rating on the stock in a research note on Wednesday, May 1st. Needham & Company LLC cut their price objective on shares of Inari Medical from $72.00 to $57.00 and set a "buy" rating for the company in a research report on Wednesday, May 1st. Truist Financial decreased their target price on Inari Medical from $61.00 to $52.00 and set a "hold" rating on the stock in a research report on Friday, March 22nd. Finally, Piper Sandler dropped their price target on Inari Medical from $55.00 to $50.00 and set a "neutral" rating for the company in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $65.71.

Insider Buying and Selling at Inari Medical

In other news, CFO Mitch C. Hill sold 6,000 shares of Inari Medical stock in a transaction on Friday, April 12th. The stock was sold at an average price of $40.96, for a total value of $245,760.00. Following the transaction, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Mitch C. Hill sold 6,000 shares of the firm's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $40.96, for a total value of $245,760.00. Following the sale, the chief financial officer now directly owns 181,294 shares in the company, valued at approximately $7,425,802.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William Hoffman sold 1,451 shares of the company's stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $40.00, for a total transaction of $58,040.00. Following the transaction, the director now owns 999,782 shares of the company's stock, valued at $39,991,280. The disclosure for this sale can be found here. Insiders sold a total of 86,000 shares of company stock worth $3,568,058 over the last three months. Corporate insiders own 10.60% of the company's stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.